Should you consider NYSE:HAE for quality investing?

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if HAEMONETICS CORP/MASS (NYSE:HAE) is suited for quality investing. Investors should of couse do their own research, but we spotted HAEMONETICS CORP/MASS showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

Looking into the quality metrics of HAEMONETICS CORP/MASS

• The 5-year revenue growth of HAEMONETICS CORP/MASS has been remarkable, with 5.27% increase. This showcases the company's strong performance in driving revenue growth and indicates its competitiveness within the market.
• HAEMONETICS CORP/MASS exhibits a strong ROIC excluding cash and goodwill, indicating efficient capital utilization and profitable operations. The 19.98% reflects the company's ability to generate returns on invested capital and underscores its commitment to delivering value to shareholders.
• The Debt/Free Cash Flow Ratio of HAEMONETICS CORP/MASS stands at 4.7, reflecting the company's prudent capital structure and cash flow dynamics. This ratio highlights the company's ability to generate robust free cash flow relative to its debt obligations.
• With a favorable Profit Quality (5-year) ratio of 124.0%, HAEMONETICS CORP/MASS showcases its ability to consistently deliver high-quality profits. This metric signifies the company's financial strength and its capacity to generate sustainable earnings over an extended period.
• HAEMONETICS CORP/MASS has experienced impressive EBIT growth over the past 5 years, with 12.23% increase. This reflects the company's effective operational performance and highlights its potential for long-term financial success.
• With EBIT 5-year growth outpacing its Revenue 5-year growth, HAEMONETICS CORP/MASS showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

What else is there to say on the fundamentals of NYSE:HAE?

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, HAE scores 7 out of 10 in our fundamental rating. HAE was compared to 204 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making HAE a very profitable company, without any liquidiy or solvency issues. HAE is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make HAE a good candidate for growth and quality investing.

Check the latest full fundamental report of HAE for a complete fundamental analysis.

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.